Hikma Will Continue To Reject Potential Takeovers

According to the CEO of Jordan's Hikma Pharmaceuticals, the firm will continue to reject any takeover offers until it reaches a market value of US$7.7bn. This stance is in line with its recent history during which the firm has refused seven approaches during the last three years. Even then, the prospect of selling is unlikely to happen immediately as the CEO's family owns a 31% stake in the firm - protecting it from hostile bidding. In our view, the refusal to sell anytime soon is a strength - despite the expected disappointment among multinational drugmakers hoping to use Hikma as

To read the full article, please choose one of the following options: